“As payers have moved away from the idea that they are practicing medicine, a lot of the quality standards [developed by specialty societies] and standards of care ... have moved not only from managing things from a quality perspective, [but also] are now linked to coverage.”

— Jo Ellen Slurzberg, VP for reimbursement and health policy at holding company Almyra, speaking at this week’s MDMA reimbursement conference, “Panel: specialty society ‘say’ on reimbursement is growing,” pp. 1, 6